Provenance Wealth Advisors’s GSK GSK Stock Holding History

Provenance Wealth Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.6K	Hold	240	–	–	﹤0.01%	326
2026 Q1	$13.2K	Hold	240	–	–	﹤0.01%	298
2025 Q4	$11.8K	Hold	240	–	–	﹤0.01%	296
2025 Q3	$10.4K	Hold	240	–	–	﹤0.01%	323
2025 Q2	$9.22K	Sell	240 -94	-28%	-$3.59K	﹤0.01%	314
2025 Q1	$12.9K	Hold	334	–	–	﹤0.01%	306
2024 Q4	$11.3K	Hold	334	–	–	﹤0.01%	307
2024 Q3	$13.7K	Hold	334	–	–	﹤0.01%	316
2024 Q2	$12.9K	Hold	334	–	–	﹤0.01%	282
2024 Q1	$14.3K	Hold	334	–	–	﹤0.01%	296
2023 Q4	$12.4K	Buy	334 +94	+39%	+$3.38K	﹤0.01%	300
2023 Q3	$8.7K	Buy	+240	New	+$8.52K	﹤0.01%	250

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Provenance Wealth Advisors's GSK Position: Q2 2026 in Review

Provenance Wealth Advisors held its GSK (GSK) position steady in Q2 2026 at 240 shares worth $12.6K. The position accounts for ﹤0.01% of the portfolio, ranked #326.

Provenance Wealth Advisors first reported a position in GSK in Q3 2023 and has held it in 12 quarters since. The position peaked at $14.3K in Q1 2024. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Provenance Wealth Advisors held 240 shares of GSK worth $12.6K as of Q2 2026.
Provenance Wealth Advisors left its GSK share count unchanged in Q2 2026.
GSK made up ﹤0.01% of Provenance Wealth Advisors's portfolio in Q2 2026, its #326 holding.
Provenance Wealth Advisors first reported a position in GSK in Q3 2023 and has held it in 12 quarters since.
Provenance Wealth Advisors's GSK position peaked at $14.3K in Q1 2024.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Provenance Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.